Eduardo Slatopolsky honored with 2007 ISN Amgen International Prize
... Established in 2003, the ISN Amgen International Prize recognizes those who have increased the understanding and treatment of kidney disease through basic or clinical scientific research, leading to therapeutic advances. This year's priz...2007 Amgen Biochemical Engineering Award
) and Amgen, Inc. are proud to announce Professor George Georgiou of the University of Texas (UT) at Austin as the winner of the 2007 Amgen Biochemical Engineering Award.... Professor Georgiou holds the Cockrell Family Reagents Chair at the UT Austin, with a primary appointment in the Department of Chemical Engineering and further appointments in the departments of Biomedical Engineering, Molecu...Amgen launches Aranesp prefilled Sureclick autoinjector for treatment of anemia
... "With the availability of the Aranesp prefilled SureClick autoinjector, healthcare providers and patients now have a new secure and simple option that automatically delivers a complete subcutaneous injection in a single use," said Willard Dere, MD, senior vice president for global de...Amgen's decision to block reinstatement of GDNF is faulted by a leading Parkinson's advocacy group
New York, February 11 The following statement is being released by the Parkinson's Disease Foundation, located at 710 West 168th Street, New York City. It follows the announcement, earlier today, of a decision by Amgen Incorporated, manufacturer of GDNF, an experimental neural growth factor, to forgo the offer of reinstatement of GDNF to patients who were involved in recent clinical trials of...ASBMB-Amgen Award Lecture to focus on orphan nuclear receptors
Barry Forman, Principal Investigator and Assistant Professor at the Beckman Research Institute of the City of Hope National Medical Center and the Gonda Diabetes Center, has been selected to receive the 2005 ASBMB-AMGEN Award. Dr. Forman's award lecture, which will take place at 8:30 a.m. on Sunday, April 3 at the American Society for Biochemistry and Molecular Biology (ASBMB) Annual Meeting in S...Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
SEATTLE (October 03, 2004) Amgen Inc. (NASDAQ: AMGN), the world's largest biotechnology company, today announced that at all doses studied, twice yearly injections of AMG 162, the company's investigational therapy for bone loss, significantly increased bone mineral density (BMD) at the total hip compared with placebo at 12 months. AMG 162, at all doses, also increased total hip BMD, similar to o...